Having been established since 1992, PIA has grown to enjoy a significant reputation by working in partnership with our clients to provide a wide range of specialist insurance products for companies in the Life Science, Bio, Medical Technology and Healthcare sectors.
Being based in the Midlands, we are centrally placed to develop lasting relationships with businesses throughout the UK and Overseas.
Being based in the Midlands, we are centrally placed to develop lasting relationships with businesses throughout the UK and Overseas.
Pioneer Group is a leading force in life sciences and tech, providing cutting-edge lab and office spaces, investment, and expertise to fuel innovation. We support ambitious start-ups, scale-ups, and established firms with world-class facilities, strategic funding, and tailored business guidance.
Our campuses connect scientists, entrepreneurs, and investors, accelerating breakthroughs in health, sustainability, and technology. By fostering collaboration and long-term partnerships, we create dynamic environments where ideas flourish, businesses scale, and industries evolve. Pioneer Group is committed to shaping the future by bridging science and business, driving economic growth, and delivering meaningful impact.
Our campuses connect scientists, entrepreneurs, and investors, accelerating breakthroughs in health, sustainability, and technology. By fostering collaboration and long-term partnerships, we create dynamic environments where ideas flourish, businesses scale, and industries evolve. Pioneer Group is committed to shaping the future by bridging science and business, driving economic growth, and delivering meaningful impact.
No data available
No data available
Prime.io Ltd – We edit genes to accelerate drug discovery
Prime.io is a gene editing contract research organization (CRO) that uses AI-designed gene editing technology and automation to edit genes and accelerate drug discovery. The company is backed by a U.S.-based venture capital firm 50Y as well as Sir Tony Kouzarides.
Cell line engineering services are available in the market but are far from reaching their full potential. Speed, quality, and scalability remain three key challenges facing the drug discovery industry when working with current endogenous gene editing service providers.
The Prime.io team brings over 50 years of combined gene editing experience. Together with a proprietary AI-powered genome editor and automated platform, this enables drug discovery scientists to obtain high-quality endogenous gene-edited clones faster and at scale. This allows drug discovery companies to generate downstream functional cellular validation data more efficiently and make critical decisions faster and with greater confidence.
Prime.io was founded in 2025 by Dr. Rex Li, CEO. The company is based at the London BioScience Innovation Centre (LBIC), 2 Royal College Street, London NW1 0NH.
To learn how we can accelerate your drug discovery research, please contact us:
Website: www.primeio.co.uk
LinkedIn: https://www.linkedin.com/company/108341309
Email: [email protected]
Prime.io is a gene editing contract research organization (CRO) that uses AI-designed gene editing technology and automation to edit genes and accelerate drug discovery. The company is backed by a U.S.-based venture capital firm 50Y as well as Sir Tony Kouzarides.
Cell line engineering services are available in the market but are far from reaching their full potential. Speed, quality, and scalability remain three key challenges facing the drug discovery industry when working with current endogenous gene editing service providers.
The Prime.io team brings over 50 years of combined gene editing experience. Together with a proprietary AI-powered genome editor and automated platform, this enables drug discovery scientists to obtain high-quality endogenous gene-edited clones faster and at scale. This allows drug discovery companies to generate downstream functional cellular validation data more efficiently and make critical decisions faster and with greater confidence.
Prime.io was founded in 2025 by Dr. Rex Li, CEO. The company is based at the London BioScience Innovation Centre (LBIC), 2 Royal College Street, London NW1 0NH.
To learn how we can accelerate your drug discovery research, please contact us:
Website: www.primeio.co.uk
LinkedIn: https://www.linkedin.com/company/108341309
Email: [email protected]
PASM offers clinical trial support services, with special expertise in helping SMEs. Projects undertaken span planning a clinical trials program to meet a regulatory strategy, through to designing and implementing outsourcing strategies to fit the company's needs.
No data available
Protogenia Consulting Ltd offers non-clinical and early clinical development consultancy services, with more than 15 years' outsourcing and project management experience gained through virtual and mid-sized pharmaceutical companies. The services offered include: strategic planning to enable early clinical development and product registration; non-clinical and clinical project management; regulatory submission writing/review/sign-off (e.g. CTA/IND, MAA/NDA, IMPD and IB); and CRO selection and study management – clinical (up to Phase 2) and non-clinical (toxicology, safety pharmacology, ADME, bioanalysis). In addition, we have a broad network of contacts, for expert advice on IP, CMC, analytical services, regulatory affairs and quality assurance.
The Provence Promotion economic development agency has been supporting business investment in Provence for close to two decades. The agency was created by the Bouches-du-Rhône Departmental Government and the Chamber of Commerce and Industry for Marseille Provence, with the Aix-Marseille-Provence Metropolis later joining as a third partner.
QRC Consultants, experienced professionals dedicated to providing high quality, cost-effective support to biopharmaceutical companies in early clinical development. We offer technical expertise with strengths including: understanding of the regulatory environment governing clinical trials globally; regulatory agency meetings and submissions – trial management, and monitoring and audit of trials; and small molecules, biological and advanced therapies. Services include: quality assurance – setup and maintenance of QMS, GCP audits and agency inspection preparation; regulatory affairs – technical document writing, SME and EU legal representative services, and bespoke procedural and GCP training; and clinical trial support – project management and monitoring.